米国の静注液の市場規模、シェア、動向分析レポート：製品別、栄養別、最終用途別、セグメント別予測、2025年～2030年

米国の静注液市場の成長と動向：

Grand View Research社の最新レポートによると、米国の静注液市場規模は2030年までに79億1,000万米ドルに達すると予測され、予測期間中のCAGRは7.8%で成長すると予測されています。

同市場は、疾患の有病率の増加や外科手術の増加により成長を遂げています。がん、神経疾患、心血管疾患、脊椎損傷などの非伝染性疾患にかかりやすい高齢化も市場拡大の原動力となっています。2024年10月、フレゼニウス・メディカル・ケア社は、透析医療の混乱を緩和するための取り組みを発表しました。同社は世界な生産施設を活用し、透析液と輸液の生産を強化しています。保健福祉省に促され、フレゼニウス・メディカル・ケアは生産戦略の改善を通じて、輸液と腹膜透析（PD）製品の需要に応えることを約束しました。

点滴静注療法は、特に糖尿病や腎臓病などの慢性疾患を持つ人において、体内の電解質バランスを補充することで、重度の脱水を効果的に治療します。主な治療法は生理食塩水で、水に塩化ナトリウムを混ぜたものです。グルコース、デキストロース、レブロースのような糖分を含む溶液も標準的です。2023年12月、輸液療法と技術の著名企業であるバクスターは、ノースウェスタン医学部との提携による輸液バッグのリサイクル試験の第一段階を終了しました。このプログラムにより、6トンを超えるPVC製点滴バッグが埋立地に廃棄されるのを防ぐことに成功しました。これらのバッグを端から端まで並べると、シカゴ全土に広がることになり、このプロジェクトが環境保全に貢献していることが実証されました。

米国の静注液市場レポートハイライト：

• 完全非経口栄養（TPN）タイプは、経口摂取や消化管からの栄養吸収ができない患者に必要な栄養素を血流に直接供給するという重要な役割を担っているため、2024年には67.14％の最大の売上シェアを占めました。
• 栄養素別では、単回投与アミノ酸溶液セグメントが2024年に31.33%の市場シェアを占め、このセグメントを独占しました。これらのソリューションは、特定の患者のニーズに合わせて調整され、身体機能の回復と維持に必要な十分なアミノ酸を確実に摂取できます。
• ビタミン・ミネラル分野は、予測期間中に最も速いCAGRで成長すると予想されます。これらの微量栄養素は、特にTPNや他の形態の非経口栄養を受けている患者において、様々な代謝プロセスや健康全般に不可欠です。
• 最終用途に関しては、急性期医療環境における重要な役割のため、病院セグメントが2024年の市場シェア46.0％でセグメントを支配しています。病院は、手術や救急医療を含むさまざまな医療処置のために静注液の安定供給を必要とするため、この市場で不可欠なプレーヤーとなっています。
• 在宅部門は、患者にとってより便利で費用対効果の高い在宅治療への嗜好の高まりから、予測期間中に最も速いCAGRで成長すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の静注液市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の静注液市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 米国の静注液市場：製品推定・動向分析

• 米国の静注液市場：製品ダッシュボード
• 米国の静注液市場：製品変動分析
• 米国の静注液市場：製品別収益
• 完全静脈栄養（TPN）
• 末梢静脈栄養（PPN）

第5章 米国の静注液市場：栄養の推定・動向分析

• 米国の静注液市場：栄養ダッシュボード
• 米国の静注液市場：栄養変動分析
• 米国の静注液市場：栄養別収益
• 炭水化物
• アミノ酸単回投与
• ビタミンとミネラル
• 非経口脂質乳剤
• その他

第6章 米国の静注液市場：最終用途の推定・動向分析

• 米国の静注液市場：最終用途ダッシュボード
• 米国の静注液市場：最終用途変動分析
• 米国の静注液市場：最終用途別収益
• 自宅
• 病院
• 点滴センター

第7章 競合情勢

• 主要メーカーによる最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2024 年
• 企業プロファイル
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Baxter
  • B. Braun Melsungen AG
  • JW Life Science
  • ICU Medical, Inc.
  • Grifols USA, LLC
  • Amphastar Pharmaceuticals, Inc.
  • Athenex, Inc.
  • Rockwell Medical, Inc.
  • Exela Pharma Sciences, LLC

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. Intravenous solutions market, by type, 2018 - 2030 (USD Billion)
• Table 3 U.S. Intravenous solutions market, by nutrients, 2018 - 2030 (USD Billion)
• Table 4 U.S. Intravenous solutions market, by end use, 2018-2030 (USD Billion)
• Table 5 Participant's overview
• Table 6 Financial performance
• Table 7 Key companies undergoing expansions
• Table 8 Key companies undergoing acquisitions
• Table 9 Key companies undergoing collaborations
• Table 10 Key companies launching new products
• Table 11 Key companies undergoing partnerships
• Table 12 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. intravenous solutions market: market outlook
• Fig. 9 U.S. intravenous solutions competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 U.S. intravenous solutions market driver impact
• Fig. 14 U.S. intravenous solutions market restraint impact
• Fig. 15 U.S. intravenous solutions: Product movement analysis
• Fig. 16 U.S. intravenous solutions: Product outlook and key takeaways
• Fig. 17 Total parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 18 Peripheral parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 19 U.S. intravenous solutions: Nutrients movement analysis
• Fig. 20 U.S. intravenous solutions: Nutrients outlook and key takeaways
• Fig. 21 Carbohydrates market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 22 Single dose amino acids market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 23 Vitamins and minerals market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 24 Parenteral lipid emulsion market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 26 U.S. intravenous solutions: End use movement analysis
• Fig. 27 U.S. intravenous solutions: End use outlook and key takeaways
• Fig. 28 Home market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 29 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 30 Infusion center market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 31 Key company categorization
• Fig. 32 Strategy mapping

U.S. Intravenous Solutions Market Growth & Trends:

The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.

IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.

U.S. Intravenous Solutions Market Report Highlights:

• The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
• Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
• The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
• In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
• The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Nutrients
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Nutrients' outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Aging population
    • 3.2.1.3. Advancements in medical technology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs associated with IV therapy due to shortages
    • 3.2.2.2. Risk of complications
• 3.3. U.S. Intravenous Solutions Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis

• 4.1. Global U.S. Intravenous Solutions Market: Product Dashboard
• 4.2. Global U.S. Intravenous Solutions Market: Product Movement Analysis
• 4.3. Global U.S. Intravenous Solutions Market by Product, Revenue
• 4.4. Total Parenteral Nutrition (TPN)
  • 4.4.1. Total parenteral nutrition (TPN) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Peripheral Parenteral Nutrition (PPN)
  • 4.5.1. Peripheral parenteral nutrition (PPN) market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

• 5.1. Global U.S. Intravenous Solutions Market: Nutrients Dashboard
• 5.2. Global U.S. Intravenous Solutions Market: Nutrients Movement Analysis
• 5.3. Global U.S. Intravenous Solutions Market by Nutrients, Revenue
• 5.4. Carbohydrates
  • 5.4.1. Carbohydrates market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Single Dose Amino Acids
  • 5.5.1. Single dose amino acids market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Vitamins And Minerals
  • 5.6.1. Vitamins and minerals market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Parenteral Lipid Emulsion
  • 5.7.1. Parenteral lipid emulsion market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis

• 6.1. Global U.S. Intravenous Solutions Market: End Use Dashboard
• 6.2. Global U.S. Intravenous Solutions Market: End Use Movement Analysis
• 6.3. Global U.S. Intravenous Solutions Market by End Use, Revenue
• 6.4. Home
  • 6.4.1. Home market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Infusion Center
  • 6.6.1. Infusion center market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Fresenius Kabi AG
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Pfizer Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Baxter
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. B. Braun Melsungen AG
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. JW Life Science
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. ICU Medical, Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Grifols USA, LLC
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Amphastar Pharmaceuticals, Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Athenex, Inc.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Rockwell Medical, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Exela Pharma Sciences, LLC
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives